Brief: Atossa Therapeutics Says On June 1, Submitted An Investigational New Drug To FDA For Atossa's Proprietary Oral (Z)-Endoxifen Capsules
06/06/2022 19:49
June 6 (Reuters) - Atossa Therapeutics Inc ATOS.O :
* ATOSSA THERAPEUTICS - ON JUNE 1, SUBMITTED AN
INVESTIGATIONAL
NEW DRUG TO FDA FOR ATOSSA'S PROPRIETARY ORAL (Z)-ENDOXIFEN
CAPSULES
* ATOSSA THERAPEUTICS - INITIAL INVESTIGATION WILL BE A
PHASE 2
STUDY OF PREMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER
Further company coverage: ATOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary